Key result
PFO closure carries a ~21% risk of early AF driven by device effects and inflammation.
Why the study?
Supraventricular arrhythmias frequently complicate PFO closure, yet their complex pathogenesis and optimal therapeutic management remain incompletely understood.
What is the incidence, pathogenesis, and management of supraventricular arrhythmias following patent foramen ovale closure in patients with embolic stroke of unknown origin?
What is the incidence, pathogenesis, and management of supraventricular arrhythmias following patent foramen ovale closure in patients with embolic stroke of unknown origin?
Supraventricular arrhythmias, particularly atrial fibrillation, are an increasingly recognized complication following PFO closure, with recent studies reporting incidences up to 21%, necessitating individualized management strategies.
Answers are grounded in this paper and cite their sources.
May warrant arrhythmia monitoring after PFO closure; extends incidence estimates but leaves optimal strategies open.
Patent foramen ovale (PFO) closure has proven to be an effective method of reducing the risk of recurrent stroke in patients with embolic stroke of unknown origin (ESUS). One of the most recognized post-procedural complications is the de novo occurrence of supraventricular arrhythmias, mainly atrial fibrillation, in the first three months following PFO closure. Earlier studies reported the incidence to be around 3.4-7%; however, this percentage has risen in recent studies up to 21%. The pathogenesis behind this type of arrhythmia is complex and not clearly understood, although it seems that direct effects of the device on the atria, as well as an inflammatory response, are the two most prevalent mechanisms. Management of this complication might be challenging given the heterogenicity of patient characteristics, so an individualized approach is most wisely followed. This review aims to present the current data on the incidence, pathogenesis and therapeutic strategies behind this rather common concern in an era of increasing transcatheter interventions for PFO.
No takes yet. Share an insight, caveat, or question.
Karanikola et al. (2024) conducted a review in Patent foramen ovale (PFO) closure and supraventricular arrhythmias. Patent foramen ovale (PFO) closure was evaluated. Supraventricular arrhythmias, mainly atrial fibrillation, occur in up to 21% of patients in the first three months following patent foramen ovale closure, likely due to device effects and inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: